Metabolic Manipulation in Chronic Heart Failure

• Status: Completed
• Trial end date: 2011-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Conventional measures used for the treatment of chronic heart failure act predominantly by reducing the work performed by the heart. In a recent study, the investigators showed that one drug (perhexiline) substantially improved symptoms and cardiac function in heart failure. The investigators wish to confirm these findings and test whether or not this drug acts by altering the heart's energy source thus augmenting the energetic status and work efficiency of the heart.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Birmingham NHS Foundation Trust
• Collaborator: British Heart Foundation
• Treatments: Perhexiline

Criteria

Inclusion Criteria:

• Optimally-medicated idiopathic dilated cardiomyopathy

• Symptomatic ( NYHA IIb-III)

• Impaired left ventricular systolic function (EF < 40%)

Exclusion Criteria:

• Abnormal liver function tests (defined as above twice the upper limit of normal (ULN))

• Concomitant use of Amiodarone , Quinidine , Haloperidol or Selective serotonin (5HT) uptake inhibitors such as Fluoxetine and Paroxetine which may inhibit the CYP2D6 enzyme.

• Pre-existing evidence of peripheral neuropathy.

• Women of childbearing potential.

• Patients with implantable cardiac devices (or any other contraindication to MRI).

• Obesity ( BMI > 32)

• Obstructive sleep apnea syndrome

• Patients with known hypersensitivity to perhexiline

• Patients with impaired renal function (Creatinine > 250 µmol/L)

• Valvular heart disease defined as more than moderate valvular stenosis or regurgitation.

• Atrial Fibrillation